kojo-kon

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• acne [Insufficient Evidence]
• allergic rhinitis [Possibly Effective]
• beta-thalassemia [Insufficient Evidence]
• cancer prevention [Insufficient Evidence]
• cardiovascular dz prevention [Possibly Ineffective]
• cognitive decline, age-related [Insufficient Evidence]
• cognitive function [Insufficient Evidence]
• cognitive impairment [Insufficient Evidence]
• COPD [Insufficient Evidence]
• COVID-19 [Insufficient Evidence]
• diabetes mellitus, type 2 [Insufficient Evidence]
• diabetic nephropathy [Insufficient Evidence]
• HTN [Insufficient Evidence]
• hypercholesterolemia [Possibly Ineffective]
• metabolic syndrome [Possibly Ineffective]
• menstrual migraine prophylaxis [Insufficient Evidence]
• mitochondrial myopathies [Insufficient Evidence]
• nonalcoholic fatty liver dz [Possibly Ineffective]
• obesity [Possibly Effective]
• osteoarthritis [Insufficient Evidence]
• osteopenia [Insufficient Evidence]
• peritoneal dialysis [Insufficient Evidence]
• periodontitis [Insufficient Evidence]
• polycystic ovary syndrome [Insufficient Evidence]
• rheumatoid arthritis [Insufficient Evidence]
• sciatica [Insufficient Evidence]
• skin aging [Insufficient Evidence]
• ulcerative colitis [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

acne

[Insufficient Evidence]

Dose: apply 1 mcg/g gel topically qhs

allergic rhinitis, adult pts

[Possibly Effective]

Dose: 2 sprays in each nostril tid; Info: 0.1% spray

allergic rhinitis, peds pts

[Possibly Effective]

Dose: 2 sprays in each nostril tid; Info: 0.05% spray; for pts 4-17 yo

cognitive decline, age-related

[Insufficient Evidence]

Dose: 75 mg PO bid; Alt: 200-1000 mg PO qd

COPD

[Insufficient Evidence]

Dose: 10 mg PO qd x20 days/mo, then repeat tx course qmo

diabetes mellitus, type 2

[Insufficient Evidence]

Dose: 250-1000 mg PO qd

diabetic nephropathy

[Insufficient Evidence]

Dose: 500 mg PO qd; Info: used w/ losartan

obesity

[Possibly Effective]

Dose: 8-3000 mg PO qd

osteoarthritis

[Insufficient Evidence]

Dose: 500 mg PO qd; Info: used w/ meloxicam

osteopenia

[Insufficient Evidence]

Dose: 25 mg PO qd

periodontitis

[Insufficient Evidence]

Dose: 480 mg PO qd; Info: used w/ non-surgical tx

peritoneal dialysis

[Insufficient Evidence]

Dose: 150-450 mg PO qd

polycystic ovary syndrome

[Insufficient Evidence]

Dose: 800-1500 mg PO qd

rheumatoid arthritis

[Insufficient Evidence]

Dose: 1 g PO qd; Info: used w/ antirheumatic tx

sciatica

[Insufficient Evidence]

Dose: 50 mg PO qd; Info: used w/ alpha-lipoic acid, acetyl-L-carnitine and cholecalciferol

ulcerative colitis

[Insufficient Evidence]

Dose: 500 mg PO qd